NCT02401347: Talazoparib Beyond BRCA (TBB) Trial

NCT02401347
Breast Cancer Type: HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 2
Drug Category: Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: BRCA 1/2+; Brain or central nervous system (CNS) metastases- check trial for exceptions
https://ClinicalTrials.gov/show/NCT02401347

Comments are closed.

Up ↑